Argent BioPharma (ASX:RGT) executed a further deed of variation with a fund managed by US fund manager Mercer Street Capital Partners for its convertible securities agreement, according to a Wednesday filing with the Australian bourse.
The deed includes refinancing 300,000 convertible notes totaling AU$1.6 million, the filing stated. The companies also agreed to reduce the conversion price to no less than AU$0.30 from at least AU$10.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。